Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
Launched by UNIVERSITY OF PENNSYLVANIA · Apr 5, 2007
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the genetic factors that may increase the risk of developing primary graft dysfunction (PGD) after a lung transplant. PGD is a serious condition that can happen in the days following the surgery, leading to severe lung injury. By understanding which genetic traits might contribute to this risk, researchers hope to improve patient outcomes and provide better care for individuals undergoing lung transplants.
To participate in this study, individuals must be planning to have a lung transplant. The trial is open to anyone aged 18 and older, regardless of gender. Participants will be asked to provide genetic information, which may involve blood tests, and they will be monitored for signs of PGD after their surgery. This research is important as it could help identify patients who might be at higher risk for PGD, allowing for more personalized treatment and support during their recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Undergoing lung transplant surgery
- Exclusion Criteria:
- • - Individuals undergoing multi-organ transplantation except heart/lung transplants
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Jason D. Christie, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials